Abstract #0857

GLINT: GlucoCEST in neoplastic tumors at 3 T – preliminary application in glioma patients using optimized preparation, imaging, and post-processing

Kai Herz¹, Tobias Lindig², Anagha Deshmane¹, Benjamin Bender², Xavier Golay³, Ulrike Ernemann², Klaus Scheffler^1,4, and Moritz Zaiss¹

¹High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany, ²Department of Diagnostic and Interventional Neuroradiology, Eberhard-Karls University Tuebingen, Tuebingen, Germany, ³Institute of Neurology, University College London, London, United Kingdom, ⁴Department of Biomedical Magnetic Resonance, Eberhard-Karls University Tuebingen, Tuebingen, Germany

Dynamic glucoCEST at clinical field strengths is very challenging due to the low effect size. Here, we present a saturation, imaging and post-processing protocol for minimizing possible artifacts to detect dynamic CEST effects reliably, and demonstrate the application in two glioblastoma patients at 3 T.

This abstract and the presentation materials are available to members only; a login is required.

Join Here